Erkkola R, Kanto J, Allonen H, Kleimola T, Mäntylä R
Int J Clin Pharmacol Biopharm. 1978 Dec;16(12):579-80.
Methylergometrine concentrations in the maternal plasma and breast milk were determined by a radioimmunoassay during continuous treatment with 0.125 mg of methylergometrine 3 times daily. On the fifth postpartum day at 8:00 a.m. the patients (n=8) took 2 tablets of Myomergin (0.250 mg of methylergometrine) orally, and the levels in the plasma and milk were determined at 1 and 8 hr after the drug administration. Measurable amounts of the drug were found only in 5 out of 16 milk samples. It was concluded that this oxytocic drug does not appear in the breast milk in quantities sufficient to affect the infant. No cumulation in the plasma or in the breast milk was found.
在每日三次连续给予0.125毫克甲基麦角新碱的治疗过程中,通过放射免疫分析法测定母体血浆和母乳中的甲基麦角新碱浓度。产后第五天上午8点,患者(n = 8)口服2片麦角新碱(0.250毫克甲基麦角新碱),并在给药后1小时和8小时测定血浆和乳汁中的水平。在16份乳汁样本中,仅在5份中检测到可测量量的药物。得出的结论是,这种催产药在母乳中的含量不足以影响婴儿。未发现血浆或母乳中有蓄积现象。